NAYA (NAYA Biosciences) Retained Earnings : $-63.54 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is NAYA Biosciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. NAYA Biosciences's retained earnings for the quarter that ended in Sep. 2024 was $-63.54 Mil.

NAYA Biosciences's quarterly retained earnings declined from Mar. 2024 ($-59.42 Mil) to Jun. 2024 ($-61.91 Mil) and declined from Jun. 2024 ($-61.91 Mil) to Sep. 2024 ($-63.54 Mil).

NAYA Biosciences's annual retained earnings declined from Dec. 2021 ($-38.89 Mil) to Dec. 2022 ($-49.78 Mil) and declined from Dec. 2022 ($-49.78 Mil) to Dec. 2023 ($-57.82 Mil).

NAYA Biosciences Retained Earnings Historical Data

The historical data trend for NAYA Biosciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NAYA Biosciences Retained Earnings Chart

NAYA Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-23.89

-32.24

-38.89

-49.78

-57.82

NAYA Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Retained Earnings	Get a 7-Day Free Trial															-55.82	-57.82	-59.42	-61.91	-63.54

NAYA Biosciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

NAYA Biosciences (NAS:NAYA) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

NAYA Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NAYA Biosciences (NAS:NAYA) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

5582 Broadcast Court, Sarasota, FL, USA, 34240

Website

https://www.nayabiosciences.com

NAYA Biosciences operates a healthcare services fertility business as well as expand its focus to the development of first-in-class clinical-stage assets in oncology and autoimmune diseases.

Executives

Trent D Davis	director	811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot	director	802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum	director	9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren	officer: Chief Financial Officer	110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan	director	22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell	director	61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina	director	5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal	director	INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody	director, officer: Medical Director	1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes	officer: Acting CFO and PFO	1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux	10 percent owner	8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff	director, officer: CEO/Chairman	109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr	officer: Chief Financial Officer	92 GOULD STREET, WAKEFIELD MA 01880